At CES 2026, health tech startup Vivoo just turned the everyday menstrual pad into a medical device. The company's new FlowPad measures follicle-stimulating hormone (FSH) levels directly on the pad itself, letting users track fertility and hormonal health without a lab visit. At $4 to $5 per pad, it's betting that women want reproductive insights built into something they're already using.
The menstrual pad just got a lot smarter. At CES 2026, health tech startup Vivoo announced the FlowPad, a roughly $4 to $5 menstrual pad that doubles as an at-home hormone test for follicle-stimulating hormone (FSH). Users can view results directly from the pad itself or snap a photo with the Vivoo app for deeper insights into their hormonal patterns.
Wellness tech companies have been getting increasingly aggressive about turning bodily fluids into health data points. From sweat to saliva to blood, the market's been flooded with devices trying to extract actionable health information from whatever the body produces. But embedding a hormone test directly into something people use multiple times a month? That's a different kind of genius, or at least a different kind of audacious.
"We started as a vaginal pH tracking liner for your panties that would change color with vaginal discharge," Vivoo CEO and cofounder Miray Tayfun tells The Verge. "It's evolved into a period pad with microfluidic channels that capture blood, and under the pad, there's a window that shows your FSH levels." The concept sounds simple enough, but the engineering underneath is where things get complex.
The main challenge? Blood dries fast. Most at-home blood tests require users to dilute samples with a solution before testing. Vivoo had to solve that problem while keeping the pad thin enough to actually wear. The solution involved a two-layer design. The first layer, what they call a "capillary capture layer," draws in blood and filters out particulates. The second layer, the "biomarker reaction layer," contains stabilized reagents that chemically react with the blood to detect FSH levels. Essentially, you bleed into the pad during your normal day, and when you change it, you get your results displayed in a window on the back that looks remarkably similar to a pregnancy test.
Tayfun emphasized that the real innovation here isn't just the technology but the philosophy behind it. "The main goal here is to make one hygienic pad less than $5, so a period won't cost you more than $30," she told The Verge. It's a pointed reminder that menstrual products remain expensive for many people, and adding $50+ in testing costs on top of that isn't realistic for widespread adoption.
The pads are designed to be worn on the second or third day of a cycle, when FSH levels are typically highest and most detectable. Depending on what users are trying to figure out, they could wear them for a few months continuously or intermittently. Vivoo estimates pricing at $4 to $5 per pad, with subscription and pack configurations coming closer to launch. For now, access will roll out first to researchers, medical partners, and people already using Vivoo's other products.
Why FSH specifically? High levels can signal lower ovarian reserves, fertility issues, or conditions like polycystic ovary syndrome (PCOS). It's useful for anyone trying to understand their fertility window, treat hormonal conditions, or figure out if they're moving toward perimenopause. The ideal user, according to Tayfun, is someone in their 30s to mid-40s, though it could work for anyone interested in tracking hormonal shifts.
This isn't the first time menstrual health has gotten the tech treatment. A few years back, there was Emm, a smart menstrual cup that packed biosensors to track flow and reproductive health. At-home hormone kits and testing devices seem to be gaining real traction too, fueled by the broader wellness obsession with "balancing hormones." Vivoo's move is notable because it eliminates a friction point, adding testing capability to something women are already buying and using.
The startup landscape around female reproductive health is heating up, and Vivoo's bet is that convenience and affordability will drive adoption where previous generations of femtech struggled. If the FlowPad actually ships at the promised price point with reliable results, it could become the first hormone test that's truly integrated into everyday life rather than bolted onto existing products.
Vivoo's FlowPad represents a subtle but significant shift in how health tech approaches women's reproductive health. Rather than asking users to adopt new devices or behaviors, it's embedding technology into something they already rely on. If it works as advertised and hits those price targets, it could set a template for how femtech moves beyond the niche wellness space into genuine healthcare utility. The real test won't be the innovation itself but whether women actually want their menstrual pads talking to their phones, and whether the data these pads collect actually helps people make better health decisions.
